Company

As new concepts for drug discovery in the post-genomic age continue to be introduced, synthetic organic chemistry continues to be pivotal to the success of these programs. Adesis, Inc. is a contract research organization (CRO) specializing in organic synthesis.

We specialize in the synthesis of milligrams to kilogram quantities including:

-Early stage proof-of-concept (POP) projects to validate biological hypotheses
-Validation of screening hits for exploratory medicinal chemistry (hit-to-lead)
-In-depth structure-activity relationship (SAR) studies
-Intermediates for expediting med chemistry SAR campaigns
-Drug candidates for in vivo studies
-Reference agents for bioprofiling
-Reference metabolites
-Building blocks for combinatorial chemistry
-Key intermediates for pharmaceuticals
-Key intermediates for biomaterial and biosensor applications

Outsourcing should be a strategic component of any sponsor's research and development portfolio, instead of an ad hoc decision. It is a decision which factors in 1) cost-risk benefits (internal vs. external), 2) timing, 3) potential CRO's skillset capabilities and business practices. In medicinal chemistry, this strategy allows in-house chemists to focus on the design and assembly of new lead molecules vs. routine syntheses which can be outsourced. Virtual biopharmaceutical companies have embraced outsourcing in order to direct maximum start-up funds to reaching proof-of-concept instead of immediate creation of infra-structure.